• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Early high-titer plasma therapy may reduce progression of COVID-19 in older patients

byThomas SuandDeepti Shroff Karhade
January 26, 2021
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients aged 65 years or greater who received convalescent plasma within 72 hours of symptom onset were less likely to develop severe respiratory disease compared to those who received placebo.

2. These benefits appeared to be dose-dependent, with higher donor antibody concentrations conferring greater protection upon the recipients.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While many potential treatments for COVID-19 have been examined, few have shown conclusive evidence of benefit in the early stages of the disease. Convalescent plasma is inexpensive and readily available, and infusions have been found to be safe and effective against other contagious diseases. However, their utility in treating COVID-19 remains ambiguous, potentially due to administration only after symptoms had already worsened. This study aimed to determine whether earlier treatment with convalescent plasma against SARS-CoV-2 would prevent disease progression in older individuals. Those who received convalescent plasma had higher concentrations of anti–SARS-CoV-2 serum Spike IgG at 24 hours relative to placebo. These patients were half as likely to develop severe respiratory disease compared to those who received placebo and also had a significantly longer median time to such an event versus placebo. Numerically fewer patients in the convalescent plasma group reached each of the secondary end points including life-threatening respiratory disease, critical systemic illness, and death. These effects were noted to be dose-dependent, as those who received donor plasma at a titer above the median concentration had a roughly two-fold reduction in relative risk compared to those who received plasma at a titer below the median concentration. While further research is needed to evaluate long-term outcomes, these results suggested that early treatment using convalescent plasma may reduce the risk of severe COVID-19 in older patients.

Click here to read the study in NEJM

Relevant Reading: Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

In-Depth [randomized controlled trial]: This double-blind, multicenter trial was conducted in Argentina from June 4 to October 25, 2020 and involved 160 patients with laboratory-confirmed COVID-19 that were either over 75 years of age or between 65 and 74 years of age with at least one prespecified coexisting condition such as hypertension, diabetes, obesity, CVD, or COPD. Randomization was completed in a 1:1 ratio, and 250 ml of either high-titer convalescent plasma (IgG titer > 1:1000 against SARS-CoV-2 spike protein) or placebo (0.9% normal saline) was administered within 72 hours of symptom onset. 24 hours after infusion, patients in the convalescent plasma group had greater concentrations of antibody titers (median log anti–SARS-CoV-2 S IgG titer, 5.7; interquartile range [IQR], 4.9 to 6.3) than in those in the placebo group (median log anti–SARS-CoV-2 S IgG titer, 3.9; IQR, 3.9 to 4.7). The primary endpoint, severe respiratory disease by day 15, occurred in 13 of 80 patients (16%) who received convalescent plasma and in 25 of 80 patients (31%) who received placebo (relative risk [RR], 0.52; 95% confidence interval [CI], 0.29 to 0.94). This effect was dose-dependent; those who received plasma at a titer at median concentration (1:3200) or greater had a RR of 0.27 (CI, 0.08–0.68), whereas those who received plasma at a titer below this concentration had an RR of 0.69 (CI, 0.34–1.31). Further, the median time to the primary endpoint was longer in the convalescent plasma group than in the placebo group (both P=0.03). A composite of life-threatening respiratory disease, critical systemic illness, or death occurred in 7 patients (9%) who received convalescent plasma and 12 patients (15%) who received placebo.

RELATED REPORTS

Hyperimmune immunoglobulin does not improve outcomes in patients hospitalized with COVID-19

Convalescent plasma is not effective at improving clinical outcomes or reducing mortality of COVID-19 patients not on mechanical ventilation

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: convalescent plasmaIgG
Previous Post

Rapid antigen testing for SARS-CoV-2 infection found to have limited accuracy for a pediatric cohort

Next Post

Omecamtiv mecarbil may be associated with decreased risk of heart-failure events

RelatedReports

Adalimumab use results in high clinical response rate in hidradenitis suppurativa
Infectious Disease

Hyperimmune immunoglobulin does not improve outcomes in patients hospitalized with COVID-19

February 16, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Emergency

Convalescent plasma is not effective at improving clinical outcomes or reducing mortality of COVID-19 patients not on mechanical ventilation

February 2, 2022
#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation
StudyGraphics

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

December 23, 2021
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

December 14, 2021
Next Post
Long-term outcomes for off-pump and on-pump CABG are similar

Omecamtiv mecarbil may be associated with decreased risk of heart-failure events

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

Clinical outcomes of COVID-19 in patients 6-months after hospital discharge in Wuhan, China

#VisualAbstract: Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction

#VisualAbstract: Oral azacytidine improves survival outcomes as maintenance therapy for patients with acute myeloid leukemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options